ADME/Tox Technologies Market Grow at a robust rate of 14.27% Forecast to 2020

ADME/Tox Technologies -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021

ADME/Tox Technologies Industry


This report on ADME/Tox Technologies gives a market insight into products and services used in the ADME/Tox industry. Predictive technologies analyzed include In vivo, In vitro, and In silico. Related technologies such as High Throughput Screening (HTS), Laboratory Information Management System (LIMS), and cell based assays are also analyzed. Market projections and estimates are illustrated by region and by technology. The report serves as a guide to ADME/Tox industry, covering more than 400 companies that are engaged in ADME/Tox studies/screening, products and services. Major Contract Research Organizations, Research Institutes and Universities serving the ADME/Tox industry are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents related to ADME/Tox Technologies is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa with 93 exclusive graphically represented exhibits.

Request for Sample Report @

Need of the Study

The current study is quite useful in choosing the right technology at the right time to conduct ADME/Tox screening of a drug candidate, to save time and money in the process of obtaining regulatory approval. ADME/Tox is a science that needs to be better understood by strategic decision makers. The risks involved and the end use applications should be major areas of research going further. ADME/Tox is considered a major hurdle in drug discovery today. Companies that produce state-of- art tools and focus on complete solutions will be clear winners. Automation is the way to go with emphasis on lower costs. Clearly, animal models cannot be totally overruled owing to the traditional concerns, and also the comfort level involved since they provide the closest biological environment to human systems.

New technologies in ADME/Tox have evolved from diverse scientific disciplines. The toughest challenge is to integrate several successful features and enable pharmaceutical companies to benefit and reap profits in the future. Though some of the concepts in this industry are still in infant stages, the data generated from other relevant sources can be used to close the gaps. Pharmaceutical companies realize the potential of ADME/Tox technologies and are trying more than before to incorporate innovative procedures to reduce drug attrition rates and lessen the burden of costs and save precious time.

Strategic partnerships between pharmaceutical and biotechnology companies are the order of the day, and the trend is increasing globally. Another significant trend is the alliance between Pharma and Biotech companies and information technology companies such as Microsoft, IBM, Oracle, Sun, and Infosys, etc. The computer platforms generated by such companies help managing and analyzing the huge amounts of data produced from ADME/Tox technologies such as High Throughput Screening (HTS) and other computational techniques. Effective R&D strategy involves efficient data management and implementation plans. The new technologies promise improved efficacy, decreased toxicity in patients, and reduced time frames and expenditures.

Global ADME/Tox Technologies market is projected to grow at a robust rate of 14.27% compounded annually from 2005 through 2020. This growth is mainly driven by the efforts of pharmaceutical and biotech companies for reducing time and cost of drug discovery. ADME/Tox profiling of a drug candidate plays a key role in reducing clinical trials cost and time of drug launch to the market. ADME/Tox assays eliminate compounds with lack of bioavailability, lower efficacy and toxicity in early stages, in order to save time and costs in expensive later stages of drug discovery. Due to ethical issues and growing trend towards decrease in using animals in clinical trials, there is a gradual decline in market for In vivo predictive technology. Though In vivo accounts for about three- fourth of total ADME/Tox Technologies market currently, non-animal technologies- In vitro and In silico are projected to peg more than 40% of the market by 2015. In particular, In silico is projected to grow at a high CAGR during the period 2005-2020. In terms of technology, In silico is projected to register the fastest growth rate in all geographic markets. ADME/Tox report is an ideal research tool providing strategic business intelligence to the corporate sector.

Leave a Query @

Reason To Buy This Report

This report may help Strategists, Investors, Laboratories, Contract Research Organizations, Biotechnology & Healthcare Companies, Academic Professionals, Drug Approval Authorities, and Other Organizations to –

Identify Market Opportunities

Review and Analyze Global and Regional Markets

Gauge Market Potential for your Products

Identify Competition

Use Market Research for exploring new areas

Acquire Meaningful Guidelines for Strategic Planning

Gear up for Market Entry

Get Actionable Information

Analytics and data presented in each report pertain to several parameters such as –

Global and Regional Market Sizes, Market Shares, Market Trends

Product (Global and Regional) Market Sizes, Market Shares, Market Trends

Technology Trends

Corporate Intelligence

Key Companies By Sales, Brands, Products

Other Strategic Business Affecting Data

Companies Discussed

53+ ADME/Tox Technologies Company Insight Profiles

428+ Company Directory Listing

Company Insight Profiles List


Accelrys, Inc. (USA)

ACE BioSciences A/S (Denmark)

Advanced Chemistry Development, Inc. (ACD/Labs) (Canada)

Agilent Technologies, Inc. (USA)

Albany Molecular Research, Inc. (USA)

Bayer Technology Services GmbH (Germany)

BD Biosciences (USA)

Beckman Coulter, Inc (USA)

BioFocus DPI Limited(UK)

Bio-Rad Laboratories, Inc. (USA)

Caliper Life Sciences, Inc. (USA)

Cambridge Cell Networks Ltd. (UK)

CeeTox, Inc. (USA)

Cellartis AB (Sweden)

Celsis International Ltd. (USA)

Cerep SA (France)

Charles River Laboratories International, Inc. (USA)

Chenomx, Inc. (Canada)

CompuDrug International, Inc. (USA)

Cyprotex plc (UK)

EMD Millipore Corporation (USA)

GE Healthcare Ltd. (UK)

Gene Logic, Inc. (USA)

GenPharmTox BioTech AG (Germany)

Harlan Laboratories, Inc. (USA)

ID Business Solutions Ltd. (UK)

Kibron, Inc. (Finland)

Korea Institute of Toxicology (South Korea)

Lhasa Limited (UK)

Life Technologies Corporation (USA)

Molecular Discovery Ltd. (UK)

MultiCASE, Inc. (USA)

Noray Bioinformatics S.L.U (Spain)

Optivia Biotechnology Inc. (USA)

PerkinElmer, Inc. (USA)

Pharmaron, Inc. (USA)

Promega Corporation (USA)

Qualyst, Inc. (USA)

Schrodinger LLC (USA)

Simcyp Ltd. (UK)

Simulations Plus, Inc. (USA)

Sirius Analytical Instruments Ltd. (UK)

Sovicell GmbH (Germany)

StemCells, Inc. (USA)

Strand Life Sciences (India)

Taconic Farms, Inc. (USA)

Tecan AG (Switzerland)

Thermo Fisher Scientific, Inc. (USA)

Tripos, Inc. (USA)

Waters Corporation (USA)

WuXi AppTec Co., Ltd. (China)

Xceleron, Inc. (USA)

Buy now @

Contact Info:
Name: Norah Trent
Email: Send Email
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +91 841 198 5042

Release ID: 150524